Offering his own version of Charles Dickens’ “A Tale of Two Cities,” FDA Office of Hematology and Oncology Products Director Richard Pazdur highlighted two real-world examples representing the best and worst of times in the quality of development programs for personalized cancer medicines.
Both therapies cited by Pazdur at a Sept. 14 conference on drug/diagnostic co-development are targeted at patients with chronic myelogenous...